Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Monobody" patented technology

Monobodies are synthetic binding proteins constructed using a fibronectin type III domain (FN3) as a molecular scaffold. Specifically, this class of binding proteins are built upon a diversified library of the 10th FN3 domain of human fibronectin. Monobodies are a simple and robust alternative to antibodies for creating target-binding proteins. The hybrid term monobody was coined in 1998 by the Koide group who published the first paper demonstrating the monobody concept using the tenth FN3 domain of human fibronectin.

Macropinocytosis-selective monobody-drug conjugate

The present disclosure relates to pharmaceutical and diagnostic compositions comprising macropinocytosis-selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain linked to a pharmaceutically active or diagnostic moiety. The present disclosure also relates to methods of treatment and diagnosis comprising administering to a subject in need thereof a pharmaceutical composition described herein. TIFF2023551388000007.tif63166
Owner:NEW YORK UNIV

Monobody and NK Cells

The present invention provides a novel substance that stably binds to a surface protein expressed on NK cells. The present invention provides a monobody that binds to a surface protein of an NK cell, wherein the monobody has an amino acid sequence of any one of (1) to (3): (1) an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12; (2) an amino acid sequence given by deletion, substitution, and / or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acids; and (3) an amino acid sequence having an identity of 80% or more with an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acid sequences, wherein X1, X2, X3, X4, X5, and X6 in SEQ ID NOs: A1 to A12 each independently represent an arbitrary amino acid, and n1, n2, n3, n4, n5, and n6 each independently represent an arbitrary natural number.X1n1 X2n2 X3n3 (SEQ ID NO: A1)PIWGRYGTTVRGQTYYWWMLX1n1X2n2 X3n3 (SEQ ID NO: A2)WTWLGYEYYWWDSKPGAIGIX1n1 X2n2 X3n3 (SEQ ID NO: A3)TYWDWGFRWSWARRTHISWFX4n4X5n5 X6n6 (SEQ ID NO: A4)PGYYMWQRGVINGQERAYGHPEHFX4n4X5n5 X6n6 (SEQ ID NO: A5)RYKYHRRINGTQWYVFNEAGDVAGYX1n1X2n2 X3n3 (SEQ ID NO: A6)GPIVSYSWWYHWVGYVNEKYDAWQSYVQX1n1X2n2 X3n3 (SEQ ID NO: A7)QAYWFEYTWWLEVVYDDQWTSGX4n4X5n5 X6n6 (SEQ ID NO: A8)TSPWYNGYDQYKSWNLEEFHX4n4X5n5 X6n6 (SEQ ID NO: A9)TPPWIHKGWVTPYGRKWVGMNGWX1n1X2n2 X3n3 (SEQ ID NO: A10)LWHYYGDQYWWMYVPEYYFNPWX1n1X2n2 X3n3 (SEQ ID NO: A11)TDRNYDITYGMQYWWDGYSYSEEAWYYX4n4X5n5 X6n6 (SEQ ID NO: A12)WSWESYWHGTYTFMKDIPSYY
Owner:GAIA BIOMEDICINE INC

Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
Owner:NAMMI THERAPEUTICS INC

Macropinocytosis selective monobody-drug conjugates

The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.
Owner:NEW YORK UNIV